SPEEDX
11.2.2020 14:02:38 CET | Business Wire | Press release
SpeeDx Pty Ltd, the developer of innovative clinical diagnostics to support improved patient outcomes, today announced it has raised $15 million in additional series B equity investment from U.S.-based Northpond Ventures. This investment comes with a company value uptick of 21.22%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005496/en/
"SpeeDx's molecular diagnostic solutions are having a profound global impact in the areas of STIs, antibiotic resistance markers, and respiratory diseases," said Michael P. Rubin, M.D., Ph.D., Founder and CEO of Northpond Ventures. "We've already seen how their diagnostic solutions for infectious diseases can translate to improved patient management, and Northpond Ventures is thrilled to continue this partnership as SpeeDx grows their global footprint."
In the U.S., SpeeDx is finalizing clinical trials for their flagship product Resistance Plus MG, detecting the STI Mycoplasma genitalium (Mgen) and genetic markers linked to antibiotic resistance of the common macrolide frontline treatment. Resistance rates in Mgen infection are steadily rising around the world, leading to difficult-to-treat infections.1-3 Recommendations for resistance testing to better inform treatment decisions can be found in Mgen management guidelines around the world.4-9 A recent partnership with Cepheid also saw the development of Resistance Plus MG on the GeneXpert® platform (available in Australia, New Zealand, and parts of Europe), as part of their FleXible cartridge program, this product was launched late 2019 and is providing clinicians with timely information to assist management of Mgen infections and adhere to management guidelines.
SpeeDx CFO Bhavin Raval said, "As we rapidly expand and enter into more collaborative partnerships, these additional funds will support the necessary structural and process investments to ensure strong pipeline and service growth throughout this year and beyond."
Pre-clinical testing is wrapping up in preparation for commencing U.S.-based clinical trials for Resistance Plus® GC—a test to determine susceptibility of gonorrhoea infections to ciprofloxacin treatment. This test has been granted Breakthrough Device designation by the FDA which will fast track the registration process. This will provide doctors and patients the option of using ciprofloxacin instead of ceftriaxone, one of the last remaining antibiotics available for multi-drug resistant gonorrhoea infections.
About SpeeDx
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com
About Northpond Ventures
Northpond Ventures is a leading global science-driven innovation firm dedicated to building and empowering breakthrough companies in life sciences and technology. Since its founding, Northpond Ventures has risen to become among the most-active investors in the life sciences and molecular diagnostics industries and is very active in all disciplines related to healthcare and affiliated industries. Its investments target the greatest scientists, innovators and entrepreneurs in life sciences, diagnostics, AI and machine learning, therapeutics, and affiliated sectors. Northpond has in excess of $500 million of committed capital, with over 20 businesses represented in its portfolio. For more information, please visit: npv.vc .
References
- Read T R H, Fairley C K, Murray G L, et al . Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation, Clinical Infectious Diseases, ciy477, https://doi.org/10.1093/cid/ciy477
- Getman D, Jiang A, O'Donnell M, Cohen S. 2016. Mycoplasma genitalium prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States. J Clin Microbiol 54:2278-2283.
- Murray GL, Bradshaw CS, Bissessor M, et al. Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium. Emerging Infectious Diseases. 2017;23(5):809-812. doi:10.3201/eid2305.161745.
- Jensen et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1650-1656.
- Horner PJ et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016 Oct;27(11):928-37.
- 2018 BASHH UK national guideline for the management of infection with Mycoplasma genitalium. Available online at: https://www.bashhguidelines.org/media/1198/mg-2018.pdf
- Groupe Infectiologie Dermatologique et Infections Sexuellement GRIDIST and Société Fançaise de Dermatologie – Press Release. Available online at: https://www.sfdermato.org/actualites/communique-commun-gridist-et-sfd.html
- Australian STI Management Guidelines – Mycoplasma genitalium 2018. http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium
- https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections/canadian-guidelines-sexually-transmitted-infections-49.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005496/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Appoints Sheng-FU Hsiao as CTOLeveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure2.3.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the appointment of Sheng-FU Hsiao as Chief Technology Officer (CTO), effective March 1, 2026. This appointment aligns with the Company’s 2026 management strategy, "Sophistication of Management Structure through AI and DX," and strengthens its leadership team to accelerate technological transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302064873/en/ SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure SBC Medical is transitioning from a traditional labor-intensive management model to an AI-driven infrastructure to address structural challenges in the m
SIMO Expands Carrier Enablement Strategy to Power Resilient, Multi-Network Enterprise Fixed Wireless Access Deployments2.3.2026 13:00:00 CET | Press release
xSIM orchestration delivers cross-network performance and unified global FWA deployment. SIMO, a leader in innovative mobile connectivity solutions, today announced the expansion of its carrier enablement strategy to power resilient, multi-network enterprise Fixed Wireless Access (FWA) deployments for both primary and backup applications. SIMO will showcase its evolution to a carrier enablement platform powering enterprise-grade FWA at Mobile World Congress 2026, in the MediaTek booth (Hall 3, Booth 3D10). “The future of enterprise FWA is not single-network, it is intelligently orchestrated multi-network connectivity,” said Eric Plam, chief revenue officer at SIMO. “By combining AI-driven local network selection with centralized global control, carriers can deliver resilient connectivity at scale while unlocking recurring managed service revenue.” Through SIMO xSIM orchestration operating at both the device firmware layer and the cloud, SIMO enables intelligent multi-network selection,
Venture Global Announces LNG Purchase Agreement with Trafigura2.3.2026 12:02:00 CET | Press release
New 5-year agreement offers flexibility and diversification to LNG portfolio Today, Venture Global, Inc. (NYSE: VG) and Trafigura announced the execution of a new, binding agreement for the purchase of approximately 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for five years commencing in 2026. This mid-term agreement offers greater flexibility to customers in the global LNG market and provides greater diversification for Venture Global’s LNG portfolio. “Trafigura is a global leader in LNG trading, and we are pleased to execute this mid-term LNG supply agreement with them to provide the market with flexible and reliable U.S. LNG,” said Venture Global CEO Mike Sabel. “Global energy demand is stronger than ever, and this is an important step in executing our strategy of adding more mid-term agreements, which will diversify the tenor of our LNG portfolio. Venture Global looks forward to helping ensure the world remains well-supplied in the sh
“AI Realized Through Display” … Samsung Display Showcases AI-Optimized OLED Technologies at MWC262.3.2026 10:58:00 CET | Press release
Introducing “Flex Magic Pixel™,” a panel-integrated privacy technology enabled by low-power, high-brightness LEAD™… Essential smartphone privacy for the AI era’s surge in personalized data usage “Thinner and tougher”… Foldable OLED durability proven with a golf putting challenge “Create your own K-pop concert”… MR experience equipped with 5,000 PPI RGB OLEDoS draws major attention New concept “edge devices” incorporating Samsung Display OLED’s unique free-form, low-power and high-resolution technologies unveiled – including the companion robot concept “Mini PetBot” and the interior décor item “AI Toy House” Spain’s Park Güell tile mosaics recreated through displays using 6.8-inch OLED and 27-inch QD-OLED, highlighting high color reproduction and bezel-less technology Eric Kim, Executive Vice President and Head of Mobile Strategic Marketing: “In the AI era, displays will evolve from simple viewing screens into intelligent interfaces that understand and respond to users and their surroun
Medimaps Group and Radiobotics Announce Strategic Merger to Expand AI-Driven Musculoskeletal Imaging Portfolio2.3.2026 09:00:00 CET | Press release
Radiobotics to join Medimaps Group, creating a global provider of AI-driven musculoskeletal (MSK) medical imaging software The transaction is expected to close following receipt of Danish foreign direct investment (FDI) approval and other customary closing conditions Together, they will bridge the gap between preventative bone health and acute trauma diagnostics, offering an expanded portfolio across X-ray and DXA: Fracture detection, opportunistic bone fragility assessment, and fracture risk prediction The combined entity will have a commercial reach in 90 countries through a robust network of direct and partner channels Both organizations will maintain their established brands, supported by close R&D and commercial collaboration Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, and Radiobotics ApS, a leader in AI-powered MSK radiology solutions, today announced that they have entered into a strategic merger agreement. Closing of the transacti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom